| |
Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to DTG + RPV 2-Drug Regimen:
SWORD-1 and -2 Studies at BHIVA
|
| |
| |
Reported by Jules Levin
25th Annual Conference of the British HIV Association; April 2-5, 2019; Bournemouth, UK
Jean van Wyk,1 Chloe Orkin,2 Rafael Rubio,3 Johannes Bogner,4 David Baker,5 Marie-Aude Khuong-Josses,6 David Parks,7
Konstantinos Angelis,8 Lesley P. Kahl,1 Jessica Matthews,9 Mark Underwood,9 Brian Wynne,9 Maria Nascimento,1
Kati Vandermeulen,10 Martin Gartland,9 Kimberly Smith9
1ViiV Healthcare, Brentford, UK; 2Queen Mary University of London, London, UK; 3HIV Unit, Department of Internal Medicine, Madrid, Spain; 4Munich University Hospital, Med IV, Munich, Germany; 5East Sydney Doctors, Darlinghurst, Sydney, Australia; 6CHG - Hôpital Delafontaine, Saint Denis Cedex, France; 7Central West Clinical Research, St Louis, MO, USA; 8GlaxoSmithKline, Uxbridge, UK; 9ViiV Healthcare, Research Triangle Park, NC, USA; 10Janssen Pharmaceutica NV, Beerse, Belgium
|
|
| |
| |
|
|
|
